Jim Cramer on Merck: “The People Who Run This Company Are Not Idiots”

Core Insights - Merck & Co., Inc. is strategically preparing for the loss of patent protection for Keytruda by making acquisitions to enhance its drug pipeline [1] - The company has focused on respiratory diseases through its acquisition of Verona, which has already launched a new maintenance treatment for chronic obstructive pulmonary disease, marking the first such treatment in over 20 years [1] - Analysts are beginning to recognize Merck's preparations for a future without Keytruda exclusivity, as evidenced by Wells Fargo's recent upgrade of the stock [1] Company Overview - Merck & Co., Inc. is a healthcare company that offers a diverse range of human and veterinary pharmaceuticals, vaccines, and health solutions [2]